Biotechnology
Camargo Pharmaceutical Services, an end-to-end drug development service provider specializing in the 505 process, has appointed K. Gary Barnette as Vice President of drug development, a key appointment as the company continues to expand. He will be ...
8 hours ago
BOSTON, May 22, 2012 /PRNewswire/-- Paratek Pharmaceuticals, Inc. today announced that Dennis Molnar, formerly Paratek's Vice President, Corporate Development, has been appointed President, Chief Executive Officer and Director, succeeding former ...
9 hours ago
New York Genome Center today announced the formal commencement of their collaborative relationship with Illumina, initiated in November 2011, when Illumina was selected as the Center's lead sequencing technology provider. As a next step in this ...
9 hours ago
The Pandemic and All-Hazards Preparedness Act Reauthorization moves to conference committee following unanimous approval by the U.S. Senate. According to Senator Richard Burr, R-N.C., the lead sponsor of the Senate bill, 'We have come a long way in ...
9 hours ago
Glytec, LLC, headquartered in Greenville, SC, announced today that its Glucommander 2.0 Enterprise software has been cleared by the FDA for pediatric use, ages 2 - 17. Glytec's Glucommander was the first insulin dosing software to be cleared for ...
9 hours ago
Emergent BioSolutions Inc. announced today that the company will be webcasting its presentation at the Jefferies 2012 Global Healthcare Conference in New York on Tuesday, June 5, 2012 at 10:30 AM Eastern. During the presentation, a member of the ...
9 hours ago
NanoViricides, Inc. , has filed its quarterly report with the Securities and Exchange Commission today, May 21st, in a timely fashion.
9 hours ago
BioCryst Pharmaceuticals, Inc. today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's clinical programs at the following investor conferences:
10 hours ago
Prosolia, Inc. and AB SCIEX announced today that they have entered into a license agreement for technologies developed by Dr. Gary Van Berkel and his colleagues of Oak Ridge National Laboratory . Dr. Van Berkel is an innovator in the field of mass ...
10 hours ago
Genetic Technologies Limited is pleased to provide an update on BREVAGen™ sales and the 'credentialing' process with the top ten U.S. Preferred Provider Organizations . To date, the Company has executed credentialing contracts with four PPOs ...
11 hours ago
MarketResearch.com has announced the addition of the new report 'Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage ...
11 hours ago
Karolinska University Hospital Sweden and GE Healthcare Life Sciences today announced a joint research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy. The three year collaboration ...
12 hours ago
Phagenesis Ltd, the global leader in the treatment of dysphagia , has been awarded c. £1 million from the Wellcome Trust to extend the scope of its dysphagia treatment device, from hospitals into the community. The Phagenesis ...
12 hours ago
MagForce signs distribution agreement with leading Russian medical device distribution company DELRUS
14 hours ago
Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA replacement therapies for cancer, announced that new preclinical data from its lead therapeutic program will be presented this week at two different conferences: 2012 TIDES ...
14 hours ago
SECTRA: Sectra's year-end report 2011/2012: Strong fourth quarter - operating profit doubled
14 hours ago
MorphoSys and Xencor Complete Enrollment in MOR208 (Xmab5574) Phase 1 Trial in CLL
15 hours ago
Medivation and Astellas Announce Submission of New Drug Application for Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated With Chemotherapy
20 hours ago
Sucampo Pharmaceuticals, Inc. today announced the presentation of positive data from a Phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction , at Digestive Disease Week 2012, held in San Diego, California. The ...
20 hours ago
Early and late stage innovators, investors and pharma partners come together at C21 BioVentures . The 14th Annual conference focuses on private companies seeking investors, collaborators and pharma partners.
22 hours ago
61 - 80 of 52760 Stories
<<
<
Next 20 Biotechnology
>
>>
Search News
